At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 110 enrolled
Drug / intervention
AKL-T01device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Improving Cognitive Health in COVID-19 Survivors Through Digital Therapeutics
In Brief
A Phase 2 clinical trial evaluating AKL-T01 for Cognitive Dysfunction and Covid19. Completed, enrolled 110 participants across 1 site.
Detailed Summary
The primary objective of this study is to investigate the efficacy of AKL-T01, a remotely-delivered digital cognitive intervention, relative to a waitlist control in improving cognitive functioning in COVID-19 survivors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCognitive Dysfunction, Covid19
CountriesUnited States
CollaboratorsAkili Interactive Labs, Inc.
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedApr 2021
Enrollment StartJul 2021
Primary CompletionFeb 2023
Study CompletionApr 2023
TodayJul 2026
First PostedApr 14, 2021
Enrollment StartJul 13, 2021
Primary CompletionFeb 6, 2023
Study CompletionApr 26, 2023
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 5.2 years ago
Interventions
AKL-T01device
AKL-T01 will be administered as a 6-week intervention. It is an algorithmically delivered iPad-based video game designed to improve cognitive health by targeting attention and attentional control processes.